more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.69 USD

-0.04 (-0.46%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $8.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

Top 32% (79 out of 250)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mazor Robotics at a 52-Week High: What's Driving the Stock?

by Zacks Equity Research Published on May 19,2017

Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.

Exactech (EXAC) Gets FDA Approval for ExactechGPS Application

by Zacks Equity Research Published on May 18,2017

Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.

Halyard Health Announces New Drainage System, Stock Down

by Zacks Equity Research Published on May 18,2017

Halyard Health (HYH), a leading medical technology company, recently announced the availability of the Halyard Enteral Drainage System, a significant addition to the company's comprehensive portfolio of enteral feeding products.

Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris

by Zacks Equity Research Published on May 16,2017

Teleflex Inc. (TFX) announced plans to introduce Arrow AC3 Optimus Intra-Aortic Balloon Pump at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) in Paris during May 16--19.

Can Inogen (INGN) Stock Continue to Grow Earnings?

by Zacks Equity Research Published on May 15,2017

Inogen, Inc (INGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

INGNNegative Net Change

Inogen (INGN) Beats Earnings and Revenue Estimates in Q1

by Zacks Equity Research Published on May 10,2017

Inogen (INGN) reported a stellar first quarter of 2017, beating the Zacks Consensus Estimate for both the counts. The company witnessed solid growth in revenues and adjusted earnings on a year-over-year basis.

Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More

by Zacks Equity Research Published on May 08,2017

Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.

Cardinal Health (CAH) Q3 Earnings Beat Estimates, Rise Y/Y

by Zacks Equity Research Published on May 01,2017

Cardinal Health Inc. (CAH) reported third-quarter fiscal 2017 adjusted earnings of $1.53 per share, which beat the Zacks Consensus Estimate of $1.46 and increased 7% on a year-over-year basis.

Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates

by Zacks Equity Research Published on May 01,2017

Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.

IDEXX Laboratories (IDXX) Beats Q1 Earnings, Raises View

by Zacks Equity Research Published on April 28,2017

IDEXX Laboratories Inc. (IDXX) recorded first-quarter 2017 earnings per share (EPS) of 77 cents, up 51% (up 53% at constant exchange rate or CER) year over year on a reported basis.

ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates

by Zacks Equity Research Published on April 28,2017

ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.

Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line

by Zacks Equity Research Published on April 28,2017

Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2017 adjusted earnings per share of 33 cents, a penny ahead of the Zacks Consensus Estimate.

athenahealth (ATHN) Misses on Earnings & Revenues in Q1

by Zacks Equity Research Published on April 28,2017

athenahealth Inc. (ATHN) reported adjusted earnings of 10 cents per share in the first quarter of fiscal 2017, which missed the Zacks Consensus Estimate by a penny.